Keeping Track: CDER Approves Its First Two Novel Agents Of 2019

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your news in brief: It took a month, but the US FDA finally issued its first novel approvals of 2019. The first went to Evolus Inc.'s Jeuveau (prabotulinumtoxinA-xvfs), a new competitor to Allergan PLC's Botox (onabotulinumtoxinA), and the second went to Sanofi's Cablivi (caplacizumab-yhdp) as the first treatment specifically indicated for acquired thrombotic thrombocytopenic purpura (aTTP).

Another drug is headed for a review under the real-time oncology review (RTOR) pilot program, as Genentech Inc. submitted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet